Gastroprotection during long-term NSAID use – what we know after 120 years of observations? Review article
Article Sidebar
Published:
Jun 30, 2021
Keywords:
gastroprotection, proton pump inhibitors, non-steroidal anti-inflammatory drugs, peptic ulcer disease
Main Article Content
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed classes of medications. The broad spectrum of side effects following long-term NSAID therapy includes mainly, but not only, gastrointestinal complications. Risk stratification of the gastrointestinal complications events is an important element of planning NSAIDs therapy, which allows to determine the indications for the use of proton pump inhibitors. This article presents the criteria for assessment and the method of adequate prevention of gastrointestinal side effects in patients receiving long-term NSAID therapy.
Article Details
How to Cite
Lipiński , M. (2021). Gastroprotection during long-term NSAID use – what we know after 120 years of observations?. Medycyna Faktow (J EBM), 14(2(51), 132-137. https://doi.org/10.24292/01.MF.0221.1
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Samborski W, Sikorska D, Niklas A et al. NLPZ a powikłania sercowo-naczyniowe i gastroenterologiczne – algorytm wyboru. Forum Reumatologiczne. 2018; 4(3): 143-51.
2. Samborski W, Filipiak KJ, Kaczmarczyk J et al. Niesteroidowe leki przeciwzapalne a powikłania sercowo-naczyniowe i gastroenterologiczne – algorytm wyboru. Choroby Serca i Naczyń. 2016; 13(4): 257-64.
3. Kossakowski B. Dużo reklam to mało szczęścia. O konsumpcyjnych obłędach i obsesjach na UG (access: 22.02.2021).
4. Sostres C, Carrera-Lasfuentes P, Lanas A. Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding: types of drug use and patient profiles in real clinical practice. Curr Med Res Opin. 2017; 33(10): 1815-20.
5. Goździalska A, Jerzy Jaśkiewicz J. Mechanizm działania niesteroidowych leków przeciwzapalnych. Państwo i Społeczeństwo. 2014; XIV(1).
6.NSAID Gastropathy (access: 13.03.2021).
7. Ahsberg K, Höglund P, Staël von Holstein C. Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010; 32: 801-10.
8. Mercadante S, Genovese G, Kargar JA et al. Home palliative care: results in 1991 versus 1988. J Pain Symptom Manage. 1992; 7: 414-8.
9. Kanno T, Moayyedi P. Who needs gastroprotection in 2020? Curr Treat Options Gastroenterol. 2020; 1-17.
10. Vaduganathan M, Bhatt DL. Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem. Clin Gastroenterol Hepatol. 2017; 15: 691-3.
11. Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev. 2001; 27: 51-61.
12. Woroń J, Wordliczek J, Dobrogowski J. Porównanie niesteroidowych leków przeciwzapalnych (NLPZ). Medycyna po Dyplomie. 2011; 20(6[183]): 55-63.
13. Malfertheiner P, Megraud F, O’Morain CA et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6-30.
14. Andersen IB, Jorgensen T, Bonnevie O et al. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population- based cohort study. Epidemiology. 2000; 11(4): 434-9.
15. Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009; 29: 481-96.
16. Mo C, Sun G, Wang YZ et al. PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis. PLoS One. 2013; 10: e0131558.
17. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998; 338: 719-26.
18. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002; (4): CD002296.
19. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol. 2005; 56(suppl 5): 5-31.
20. Gostishchev VK, Evseev MA. Patogenez retsidiva ostrykh gastroduodenal’nykh iazvennykh krovotecheniĭ [Pathogenesis of recurrences of acute gastroduodenal ulcerous bleedings]. Khirurgiia (Mosk). 2004; (5): 46-51.
21. Freigofas J, Haefeli WE, Schöttker B et al. Indirect evidence for proton pump inhibitor failure in patients taking them independent of meals. Pharmacoepidemiol Drug Saf. 2014; 23(7): 768-72.
22. Gunaratnam NT, Jessup TP, Inadomi J et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006; 23: 1473-7.
23. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000; 118: S9-S31.
24. Park SC, Chun HJ, Kang CD et al. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol. 2011; 17(42): 4647-53.
25. Yuan JQ, Tsoi KKF, Yang M et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016; 43(12): 1262-75.
26. Pilotto A, Franceschi M, Leandro G et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004; 20: 1091-7.
2. Samborski W, Filipiak KJ, Kaczmarczyk J et al. Niesteroidowe leki przeciwzapalne a powikłania sercowo-naczyniowe i gastroenterologiczne – algorytm wyboru. Choroby Serca i Naczyń. 2016; 13(4): 257-64.
3. Kossakowski B. Dużo reklam to mało szczęścia. O konsumpcyjnych obłędach i obsesjach na UG (access: 22.02.2021).
4. Sostres C, Carrera-Lasfuentes P, Lanas A. Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding: types of drug use and patient profiles in real clinical practice. Curr Med Res Opin. 2017; 33(10): 1815-20.
5. Goździalska A, Jerzy Jaśkiewicz J. Mechanizm działania niesteroidowych leków przeciwzapalnych. Państwo i Społeczeństwo. 2014; XIV(1).
6.NSAID Gastropathy (access: 13.03.2021).
7. Ahsberg K, Höglund P, Staël von Holstein C. Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010; 32: 801-10.
8. Mercadante S, Genovese G, Kargar JA et al. Home palliative care: results in 1991 versus 1988. J Pain Symptom Manage. 1992; 7: 414-8.
9. Kanno T, Moayyedi P. Who needs gastroprotection in 2020? Curr Treat Options Gastroenterol. 2020; 1-17.
10. Vaduganathan M, Bhatt DL. Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem. Clin Gastroenterol Hepatol. 2017; 15: 691-3.
11. Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev. 2001; 27: 51-61.
12. Woroń J, Wordliczek J, Dobrogowski J. Porównanie niesteroidowych leków przeciwzapalnych (NLPZ). Medycyna po Dyplomie. 2011; 20(6[183]): 55-63.
13. Malfertheiner P, Megraud F, O’Morain CA et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6-30.
14. Andersen IB, Jorgensen T, Bonnevie O et al. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population- based cohort study. Epidemiology. 2000; 11(4): 434-9.
15. Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009; 29: 481-96.
16. Mo C, Sun G, Wang YZ et al. PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis. PLoS One. 2013; 10: e0131558.
17. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998; 338: 719-26.
18. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002; (4): CD002296.
19. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol. 2005; 56(suppl 5): 5-31.
20. Gostishchev VK, Evseev MA. Patogenez retsidiva ostrykh gastroduodenal’nykh iazvennykh krovotecheniĭ [Pathogenesis of recurrences of acute gastroduodenal ulcerous bleedings]. Khirurgiia (Mosk). 2004; (5): 46-51.
21. Freigofas J, Haefeli WE, Schöttker B et al. Indirect evidence for proton pump inhibitor failure in patients taking them independent of meals. Pharmacoepidemiol Drug Saf. 2014; 23(7): 768-72.
22. Gunaratnam NT, Jessup TP, Inadomi J et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006; 23: 1473-7.
23. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000; 118: S9-S31.
24. Park SC, Chun HJ, Kang CD et al. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol. 2011; 17(42): 4647-53.
25. Yuan JQ, Tsoi KKF, Yang M et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016; 43(12): 1262-75.
26. Pilotto A, Franceschi M, Leandro G et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004; 20: 1091-7.